| Project/Area Number |
14571170
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Saitama Cancer Center |
|---|
Principal Investigator |
HAYASHI Shin-ichi Saitama Cancer Center, Research Institute, Senior researcher, 研究室, 主任研究員 (60144862)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAGUCHI Yuri Saitama Cancer Center, Research Institute, Senior researcher, 研究室・主任研究員 (80166628)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2003: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2002: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | breast cancer / estrogen receptor / nuclear receptor / transcription factor / microarray / transcriptional regulation / エストロゲンレセプター |
|---|
| Research Abstract |
Estrogen and its receptor play important roles in genesis and malignant progression of breast cancer. In particular, ERα is not only closely associated with clinical outcome of breast cancer but also most important target of endocrine therapy. We have been studied the molecular mechanisms of carcinogenesis and development of human breast cancer so far, in terms of cancer-specific phenomenon of expression and function of estrogen receptor. Recently, we have produced a custom-made cDNA microarray for analyzing estrogen-responsive gene expression profile, and applied it to several basic and clinical studies, such as understanding the estrogen signaling pathway in breast cancer cells and prediction of individual response to endocrine therapy among primary breast cancer patients. In this study, we found several novel target genes for estrogen receptor, and revealed that some of them might impact to clinical outcome of breast cancer patients. This microarray was also useful to analyze the functional modulation of ERα controlled by the intracellular factors such as ERβ. Furthermore, we are developing a new tool for analyzing the effect of new aromatase inhibitors on individual breast cancer patients using ERE-GFP-indicator cells. We hope that these approaches could provide clinical benefits to patients by assessment of individual response to endocrine therapy.
|
